1243313-45-2 Usage
Uses
Used in Neuroscience Research:
6-Fluoro-3-methylbenzo[d]isoxazol-5-amine hydrochloride is used as a potent antagonist for the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Its hydrochloride form is commonly employed in neuroscience research to study the role of NMDA receptors in various physiological and pathological processes in the central nervous system. This helps researchers understand the mechanisms underlying neurological and psychiatric disorders and develop potential therapeutic interventions.
Used in Pharmaceutical Development:
6-Fluoro-3-methylbenzo[d]isoxazol-5-amine hydrochloride may have potential applications in the development of new medications for neurological and psychiatric disorders. Its antagonistic action on the NMDA receptor's glycine site could provide a novel approach to treating conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia, and depression. By modulating the activity of NMDA receptors, 6-Fluoro-3-methylbenzo[d]isoxazol-5-amine hydrochloride could potentially alleviate symptoms and improve the quality of life for patients suffering from these disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1243313-45-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,3,3,1 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1243313-45:
(9*1)+(8*2)+(7*4)+(6*3)+(5*3)+(4*1)+(3*3)+(2*4)+(1*5)=112
112 % 10 = 2
So 1243313-45-2 is a valid CAS Registry Number.
1243313-45-2Relevant academic research and scientific papers
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-YL)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5amine
-
Page/Page column 5, (2008/06/13)
The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
